25391-60-0

Usage

Uses

Used in Pharmaceutical Industry:
2-Chloro-3-iodo-5-nitropyridine is used as an intermediate compound for the synthesis of various pharmaceuticals. Its unique structure and functional groups make it a valuable building block in the development of new drugs, potentially leading to the creation of novel therapeutic agents.
Used in Agrochemical Industry:
2-Chloro-3-iodo-5-nitropyridine is used as a precursor in the synthesis of agrochemicals, such as pesticides and herbicides. Its chemical properties allow for the creation of compounds that can effectively control pests and weeds in agricultural settings, contributing to increased crop yields and protection of crops from damage.
Used in Dye Industry:
2-Chloro-3-iodo-5-nitropyridine is used as a key component in the production of dyes. Its versatile chemical structure enables the creation of a wide range of colors and hues, making it an essential ingredient in the formulation of various types of dyes used in textiles, plastics, and other industries.

Upstream product

• 25391-58-6 2-hydroxy-3-iodo-5-nitropyridine 
• 10026-13-8 phosphorus pentachloride 
• 5418-51-9 5-nitro-2-hydroxypyridine 

Downstream Products

• 444902-32-3 5-amino-2-chloro-3-iodopyridine 
• 31676-54-7 3-amino-5-phenylpyridine 
• 1119085-63-0 5-methyl-2-(6-phenyl-5-(trifluoromethyl)pyridin-3-ylamino)benzoic acid 
• 1119088-25-3 N-(6-phenyl-5-(trifluoromethyl)pyridin-3-yl)acetamide 
• 1119088-10-6 6-phenyl-5-(trifluoromethyl)pyridin-3-amine 
• 1119088-63-9 2-cyclopropyl-5-nitro-3-phenylpyridine 
• 1119088-60-6 6-cyclopropyl-5-phenylpyridin-3-amine 
• 99368-68-0 6-chloro-5-(trifluoromethyl)pyridin-3-amine 
• 131941-24-7 5-nitro-2,3-diphenylpyridine 
• 1419600-18-2 1-((3-tert-butyl-1-(3-chlorophenyl)-1H-pyrazol-5-yl)methyl)-3-(6-(dimethylamino)-5-(trifluoromethyl)pyridin-3-yl)urea 
• 1419600-15-9 1-((1-(3-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)methyl)-3-(6-(dimethylamino)-5-(trifluoromethyl)pyridin-3-yl)urea 
• 1419603-91-0 phenyl 6-(dimethylamino)-5-(trifluoromethyl)pyridin-3-ylcarbamate 
• 288247-16-5 N₂,N₂-dimethyl-3-(trifluoromethyl)pyridine-2,5-diamine 
• 99368-67-9 2-chloro-5-nitro-3-(trifluoromethyl)pyridine 

Relevant academic research and scientific papers

PROTEASOME ACTIVITY ENHANCING COMPOUNDS

The present invention is directed to compounds having the Formula (I), (II), (III), (IV), and (V), compositions thereof, the methods of synthesis of the compouds of interest, and to methods for the treatment of a condition associated with a dysfunction in proteostasis, such as cancer, inflammatory conditions, neurodegeneration, metabolic conditions, comprising administering an effective amount of a compound of the invention.

NAPHTHALENE DERIVATIVE

The present invention provides compounds which can regulate VCP activity. The present invention provides the compound of formula (I) (R is as defined in the description) or oxides, esters, prodrugs, pharmaceutically acceptable salts or solvates thereof. The compounds can regulate VCP activity, and thus are useful for treating VCP-mediated diseases such as neurodegenerative diseases.

AZABIPHENYLAMINOBENZOIC ACID DERIVATIVES AS DHODH INHIBITORS

New azabiphenylaminobenzoic acid derivatives having the chemcial structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of the dehydroorotate dihydrogenase (DHODH)

Synthesis and in-vivo evaluation of [11C]p-PVP-MEMA as a PET radioligand for imaging nicotinic receptors

Within the class of (4-pyridinyl)vinylpyridines developed by Abbott laboratories as potent neuronal nicotinic acetylcholine receptor ligands, p-PVP-MEMA ({(R)-2-[6-chloro-5-((E)-2-pyridin-4-ylvinyl)pyridin-3-yloxy]-1- methylethyl}methylamine) is the lead compound of a novel series that do not display the traditional nicotinic-like pyrrole-ring but still possessing high subnanomolar affinity (Ki 0.077 nm?displacement of [ 3H](?)cytisine from whole rat brain synaptic membranes). In the present study, p-PVP-MEMA and its nor-derivative ({(R)-2-[6-chloro-5-((E)-2- pyridin-4-ylvinyl)pyridin-3-yloxy]-1-methylethyl}methylamine) as precursor for labelling with the short-lived positron-emitter carbon-11 (T1/2 20.4 min) were synthesized in 10 chemical steps from 2-hydroxy-5-nitropyridine and Boc-d-alanine. N-Alkylation of nor-p-PVP-MEMA with [11C]methyl iodide afforded [11C]p-PVP-MEMA (>98% radiochemically pure, specific activity of 86.4 GBq ?mol?1) in 2% (non-decay corrected and non-optimized) radiochemical yield, in 34 min (including HPLC purification and formulation). Preliminary positron emission tomography (PET) results obtained in a Papio hamadryas baboon showed that [11C]p-PVP-MEMA is not a suitable PET-radioligand. CSIRO 2008.

SUBSTITUTED HETEROCYCLES AS JANUS KINASE INHIBITORS

The present invention provides substituted tricyclic heteroaryl compounds, including, for example, pyridoindoles, pyrimidinoindoles and triazinoindoles that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases such as immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.

ORGANIC COMPOUNDS

The present invention relates to quinazolinone compounds of the formula wherein R2, R3, R5, R6 R7 and R8 are as defined in the specification and in the claims, in free form or in salt form , processes for their preparation and their use as pharmaceuticals, particularly in the treatment of disorders ameliorated by administration of TRPV1 antagonists.

Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function

Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.

Synthesis and evaluation of a novel series of 2-chloro-5-((1-methyl-2-(S)-pyrrolidinyl)methoxy)- 3-(2-(4-pyridinyl)vinyl)pyridine analogues as potential positron emission tomography imaging agents for nicotinic acetylcholine receptors

Reportedly, 2-[18F]fluoro-A-85380, 1, a promising radiotracer for imaging the nicotinic acetylcholine receptor (nAChR) by positron emission tomography (PET) in humans, exhibits slow penetration through the blood-brain barrier (BBB) due to its low lipophilicity. A ligand for nAChRs with greater lipophilicity than that of 1 would be potentially more favorable for PET imaging of nAChR due to its faster penetration through the BBB. Herein, a novel series of compounds has been developed based on the high affinity ligand for nAChRs, 2-chloro-5-((1-methyl-2-(S)-pyrrolidinyl)methoxy)- 3-(2-(4-pyridinyl)vinyl)pyridine, 3b. The in vitro binding affinities for the new series were found to be in the range of Ki = 9-331 pM. A molecular modeling study showed differences in the comformational profiles and the electronic properties of these compounds, which provides further insight into the structure-activity relationships at nAChR. Lipophilicities of the compounds 3b-6b have been found to be substantially higher than that of 1. As a result, compounds 3b-6b might exhibit a faster penetration through the BBB than the less lipophilic 1. The N-methyl derivatives 3b and 6b demonstrated very high affinities at nAChRs (Ki = 28 and 23 pM, respectively) and will be targets for development of 11CH3-labeled derivatives as radiotracers for PET imaging of nAChRs.